143703-25-7

中文名稱 143703-25-7

英文名稱 CE3F4

CAS 143703-25-7

分子式 C11H10Br2FNO

分子量 351.01

MOL 文件 143703-25-7.mol

更新日期 2026/01/06 20:30:23

143703-25-7 結(jié)構(gòu)式

基本信息物理化學(xué)性質(zhì) 安全數(shù)據(jù) 圖譜信息 143703-25-7價(jià)格(試劑級(jí)) 常見問題列表

基本信息

中文別名

化合物CE3F4

英文別名

CE3F4
CE3F4 >=98% (HPLC)
5,7-Dibromo-6-fluoro-3,4-dihydro-2-methyl-1(2H)-quinolinecarboxaldehyde
1(2H)-Quinolinecarboxaldehyde, 5,7-dibromo-6-fluoro-3,4-dihydro-2-methyl-

物理化學(xué)性質(zhì)

儲(chǔ)存條件-20°C儲(chǔ)存

溶解度Soluble in DMSO > 10 mM

形態(tài)粉末

顏色White to off-white

InChIInChI=1S/C11H10Br2FNO/c1-6-2-3-7-9(15(6)5-16)4-8(12)11(14)10(7)13/h4-6H,2-3H2,1H3

InChIKeyZZLQPWXVZCPUGC-UHFFFAOYSA-N

SMILESN1(C=O)C2=C(C(Br)=C(F)C(Br)=C2)CCC1C

安全數(shù)據(jù)

危險(xiǎn)性符號(hào)(GHS) 有害 (GHS07)

GHS07,GHS09

警示詞警告

危險(xiǎn)性描述H302-H411

防范說明P264-P270-P301+P312-P330-P501

WGK GermanyWGK 3

存儲(chǔ)類別11 - Combustible Solids

危險(xiǎn)性類別Acute Tox. 4 Oral
Aquatic Chronic 2

圖譜信息

143703-25-7(143703-25-7)核磁圖(¹HNMR)

143703-25-7價(jià)格(試劑級(jí))

報(bào)價(jià)日期	產(chǎn)品編號(hào)	產(chǎn)品名稱	CAS號(hào)	包裝	價(jià)格
2026/06/05	HY-108539	143703-25-7 CE3F4	143703-25-7	5mg	600元
2026/06/05	HY-108539	143703-25-7 CE3F4	143703-25-7	10mM * 1mLin DMSO	660元
2026/06/05	HY-108539	143703-25-7 CE3F4	143703-25-7	10mg	1000元

常見問題列表

生物活性

CE3F4 是一種選擇性的 Epac1 拮抗劑，對(duì) Epac1 和 Epac2(B) 的 IC50 值分別為 10.7 μM 和 66 μM。

靶點(diǎn)

IC50: 10.7 μM (Epac1), 66 μM (Epac2(B))

體外研究

CE3F4 is a selective antagonist of Epac1, with IC ₅₀ s of 10.7 μM and 66 μM for Epac1 and Epac2(B), respectively. CE3F4 is more active on Epac1 than (S)-stereoisomer ((S)-CE3F4, IC ₅₀ , 56 μM), but less active than (R)-CE3F4 (IC ₅₀ , 5.8 μM). CE3F4 (50 μM) shows more inhibitory activities against GEF activity of Epac1, than that of Epac2(AB) or Epac2(B). CE3F4 reduces the exchange activity of Epac1 induced by 007, with IC ₅₀ of 23 ± 3 μM. CE3F4 (40 μM) specifically inhibits Epac1 guanine nucleotide exchange activity without interference with Rap1 activity or Epac1-Rap1 interaction. CE3F4 has no influence on PKA activity. CE3F4 (20 μM) inhibits Epac-induced Rap1 activation in living cultured HEK293 cells. CE3F4 (20 μM) significantly inhibits the late phase of ERK activation stimulated by glucose in INS-1 cells.

體內(nèi)研究

CE3F4 (1-3 mg/kg; through a catheter in the internal jugular vein) inhibits atrial fibrillation (AF) and CE3F4 (3 mg/kg; i.v.) inhibits ventricular arrhythmias.
CE3F4 (10 mg/kg; i.v.) improves cardiac function after myocardial infarction in mice.

Animal Model:	Wild-type (WT) mice (induced AF after 20min of CE3F4 administration)
Dosage:	3 mg/kg and 1mg/kg
Administration:	Through a catheter in the internal jugular vein
Result:	Shortened the duration of the pacing-induced AF at 3mg/kg.

Animal Model:	Casq2-KO mice (premature ventricular contraction induced by isoproterenol injection 20min after CE3F4 administration)
Dosage:	3 mg/kg
Administration:	I.v.
Result:	Reduced the incidence of sympathetic activation-induced ventricular arrhythmias.